Supplementary materials.xlsx (485.38 kB)

Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A - Supplementary materials.xlsx

dataset

posted on 2022-05-10, 09:59 authored by Arash Mahajerin, Imi Faghmous, Peter Kuebler, Monet Howard, Tao XU, Carlos Flores, Tiffany Chang, Francis Nissen

Channeling effects in the prescription of new therapies - the case of emicizumab for hemophilia A: Supporting information

Supplementary Table 1: Code listings

Funding

F. Hoffmann-La Roche, (Grant / Award Number: )

History

Usage metrics

Read the peer-reviewed publication

Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A

Journal of Comparative Effectiveness Research

Keywords

channeling claims data coagulation factor VIII comorbidity emicizumab healthcare systems hemophilia A pharmacovigilance safety

Licence

CC BY-NC-ND 4.0